NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Rhea-AI Summary

NextCure Inc (Nasdaq: NXTC) announced two presentations at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, TX from November 6-10, 2024. The company will present:

1. Pre-clinical data on LNCB74, a B7-H4 antibody-drug conjugate, in a poster session on November 8.

2. Biomarker data from the NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L colorectal cancer, in a poster session on November 9.

These presentations showcase NextCure's ongoing research in novel cancer therapies, particularly in antibody-drug conjugates and combination immunotherapies.

Positive

• Presenting pre-clinical data on LNCB74, a potential new cancer therapy
• Sharing biomarker data from NC410 combination study, indicating progress in clinical research
• Participation in a major cancer research conference, demonstrating industry engagement

Negative

• None.

News Market Reaction

+3.05%

1 alert

+3.05% News Effect

On the day this news was published, NXTC gained 3.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions.

Poster Presentation Details:

Title: LNCB74 is a B7-H4 antibody-drug conjugate with a β-glucuronide linker-MMAE payload system to enhance therapeutic index in B7-H4 expressing cancers
Lead Author: Shannon M. Kahan
Abstract Number: 1051
Session Date & Time: Friday, November 8, 2024, 5:30 – 7:00 PM

Title: NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer (CRC)
Lead Author: Alina Barbu
Abstract Number: 632
Session Date & Time: Saturday, November 9, 2024, 7:10 – 8:30 PM

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com

FAQ

What presentations will NextCure (NXTC) give at the SITC 2024 annual meeting?

NextCure will give two poster presentations at SITC 2024: one on LNCB74, a B7-H4 antibody-drug conjugate, and another on NC410 in combination with pembrolizumab for colorectal cancer treatment.

When and where will NextCure (NXTC) present at the SITC 2024 annual meeting?

NextCure will present at the SITC annual meeting in Houston, TX from November 6-10, 2024. The LNCB74 presentation is on November 8, and the NC410 combination study presentation is on November 9.

What is the focus of NextCure's (NXTC) LNCB74 presentation at SITC 2024?

The LNCB74 presentation focuses on a B7-H4 antibody-drug conjugate with a β-glucuronide linker-MMAE payload system designed to enhance therapeutic index in B7-H4 expressing cancers.

What is the subject of NextCure's (NXTC) NC410 combination study presentation at SITC 2024?

The NC410 presentation discusses how the combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer.